Amgen

Biotechnology / Immunology

AMGN · Nasdaq · United States

Share price · AMGN

$443.89+18.61 (+4.38%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.6M (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AMGN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 22 Sep 2026+4.3%
  2. 8 Sep 2026-10.1%
  3. 5 Aug 2026+4.6%
  4. 4 Aug 2026+2.9%
  5. 11 Jun 2026+4.8%
  6. 3 Jun 2026+3.0%
  7. 15 May 2026-3.0%
  8. 1 May 2026-4.7%
  9. 4 Feb 2026+8.2%

Share of unusual movement by asset

For each asset, the share of AMGN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Tarlatamab
events and moves
87%
Evolocumab (Repatha)
events and moves
92%
Inebilizumab
events and moves
81%
tezepelumab (Tezspire)
events and moves
81%
maridebart cafraglutide (MariTide)
events and moves
4shown from 8 days
Avacopan (Tavneos)
events and moves
3shown from 8 days
Blinatumomab
events and moves
2shown from 8 days
Sotorasib
events and moves
2shown from 8 days
apremilast (Otezla)
events and moves
1shown from 8 days
aflibercept-ayyh (Pavblu) (Pavblu)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—12%
Other company news (earnings, financing, releases naming no asset)—34%
Sessions with no dated event—43%

Assets

(29 total)
29Total Assets
18Approved
6Phase 3 / Filed
5Phase 1–2 / Early
32Diseases
Quick filter:
Showing 29 of 29 assets
Target & Modality
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis
Ulcerative Colitis, Crohn's Disease
Approved
VEGF-AProtein / enzyme therapeutic
Age-Related Macular DegenerationDiabetic Macular Edema
Wet Age-Related Macular Degeneration
apremilast(Otezla)
Approved
PDE4Small molecule
Psoriatic ArthritisPsoriasis
Approved
VEGF-AMonoclonal antibody
Non-Small Cell Lung CancerCervical CancerColorectal CancerRenal Cell CarcinomaGlioblastoma
Metastatic Colorectal Cancer, Recurrent Glioblastoma, Advanced Metastatic Colorectal Cancer
Approved
CD19 x CD3Multispecific antibody
Systemic Lupus ErythematosusRheumatoid ArthritisAcute Lymphoblastic Leukemia
Approved
ProteasomeSmall molecule
Multiple Myeloma
Approved
RANKLMonoclonal antibody
Rheumatoid ArthritisOsteoporosis
Approved
CGRP receptorMonoclonal antibody
Migraine
etanercept(Enbrel)
Approved
TNF-alpha · TNF-alpha / TNF-beta (lymphotoxin-alpha)Protein / enzyme therapeutic
Psoriatic ArthritisPsoriasisRheumatoid Arthritis
Etelcalcetide(Parsabiv)
Approved
Calcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cellsPeptide
Chronic Kidney Disease
Secondary Hyperparathyroidism
Evolocumab(Repatha)
Approved
PCSK9Monoclonal antibody
Atherosclerotic Cardiovascular DiseaseHomozygous Familial Hypercholesterolemia
Approved
CD19Monoclonal antibody
Systemic Lupus ErythematosusMyasthenia Gravis
Generalized Myasthenia Gravis
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid Arthritis
Ulcerative Colitis, Crohn's Disease
Ivabradine(Corlanor)
Approved
If (funny) channelSmall molecule
Heart Failure
Approved
KRAS G12CSmall molecule
Non-Small Cell Lung CancerColorectal Cancer
Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer

Discontinued programmes (2)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(51 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Abp 234Phase 3Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2026-12-14 · NCT06430866 · CT.gov ↗
What to watch
2027 (19)
January 2027 (3)
tezepelumab · TezspirePhase 3Chronic Rhinosinusitis With Nasal Polyps
Est. primary completion 2027-01-13 · NCT06706817 · CT.gov ↗
What to watch
Est. primary completion 2027-01-21 · NCT06858839 · CT.gov ↗
What to watch
maridebart cafraglutide · MariTidePhase 3Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Est. primary completion 2027-01-21 · NCT06858878 · CT.gov ↗
What to watch
April 2027 (3)
InebilizumabPhase 2Neuromyelitis Optica Spectrum Disorder
Est. primary completion 2027-04-13 · NCT05549258 · CT.gov ↗
What to watch
ABP 692Phase 3Relapsing-remitting Multiple Sclerosis (RRMS)
Est. primary completion 2027-04-19 · NCT06700343 · CT.gov ↗
What to watch
Est. primary completion 2027-04-27 · NCT06987695 · CT.gov ↗
What to watch
June 2027 (4)
maridebart cafraglutide · MariTidePhase 3Obesity, Overweight
Est. primary completion 2027-06-16 · NCT07871409 · CT.gov ↗
What to watch
tezepelumab · TezspirePhase 3Severe Asthma
Est. primary completion 2027-06-25 · NCT06473779 · CT.gov ↗
What to watch
Etelcalcetide · ParsabivPhase 3Secondary Hyperparathyroidism
Est. primary completion 2027-06-30 · NCT03969329 · CT.gov ↗
What to watch
SotorasibPhase 3Non-Small Cell Lung Cancer (NSCLC)
Est. primary completion 2027-06-30 · NCT05920356 · CT.gov ↗
What to watch
July 2027 (1)
Avacopan · TavneosPhase 3Vasculitis
Est. primary completion 2027-07-18 · NCT06321601 · CT.gov ↗
What to watch
August 2027 (3)
maridebart cafraglutide · MariTidePhase 3Obesity, Obstructive Sleep Apnea
Est. primary completion 2027-08-20 · NCT07225686 · CT.gov ↗
What to watch
maridebart cafraglutide · MariTidePhase 2Overweight or Obesity and Elevated Liver Fat
Est. primary completion 2027-08-25 · NCT07441252 · CT.gov ↗
What to watch
maridebart cafraglutide · MariTidePhase 3Obstructive Sleep Apnea
Est. primary completion 2027-08-30 · NCT07226765 · CT.gov ↗
What to watch
September 2027 (1)
TarlatamabPhase 3Small Cell Lung Cancer
Est. primary completion 2027-09-24 · NCT07778316 · CT.gov ↗
What to watch
November 2027 (1)
BlinatumomabPhase 1/2B Cell Precursor Acute Lymphoblastic Leukemia
Est. primary completion 2027-11-24 · NCT04521231 · CT.gov ↗
What to watch
December 2027 (3)
maridebart cafraglutide · MariTidePhase 3Obesity, Overweight, Diabetes Mellitus, Type 2
Est. primary completion 2027-12-26 · NCT07684144 · CT.gov ↗
What to watch
maridebart cafraglutide · MariTidePhase 3Obesity, Overweight
Est. primary completion 2027-12-26 · NCT07684235 · CT.gov ↗
What to watch
TarlatamabPhase 2Relapsed/Refractory Small Cell Lung Cancer
Est. primary completion 2027-12-30 · NCT05060016 · CT.gov ↗
What to watch
2028 (14)
January 2028 (2)
maridebart cafraglutide · MariTidePhase 3Obesity or Overweight
Est. primary completion 2028-01-03 · NCT07575399 · CT.gov ↗
What to watch
Abp 234Phase 3Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Est. primary completion 2028-01-10 · NCT06311721 · CT.gov ↗
What to watch
February 2028 (1)
tezepelumab · TezspirePhase 3Severe Asthma
Est. primary completion 2028-02-07 · NCT07363642 · CT.gov ↗
What to watch
March 2028 (3)
tezepelumab · TezspirePhase 3Chronic Rhinosinusitis With Nasal Polyps
Est. primary completion 2028-03-01 · NCT07520162 · CT.gov ↗
What to watch
apremilast · OtezlaPhase 3Active Juvenile Psoriatic Arthritis
Est. primary completion 2028-03-21 · NCT04804553 · CT.gov ↗
What to watch
OlpasiranPhase 3Atherosclerotic Cardiovascular Disease
Est. primary completion 2028-03-31 · NCT05581303 · CT.gov ↗
What to watch
May 2028 (1)
Est. primary completion 2028-05-31 · NCT06023589 · CT.gov ↗
What to watch
June 2028 (3)
OlpasiranPhase 3Cardiovascular Disease
Est. primary completion 2028-06-15 · NCT07293260 · CT.gov ↗
What to watch
maridebart cafraglutide · MariTidePhase 3Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Est. primary completion 2028-06-30 · NCT07037433 · CT.gov ↗
What to watch
maridebart cafraglutide · MariTidePhase 3Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Est. primary completion 2028-06-30 · NCT07037459 · CT.gov ↗
What to watch
July 2028 (1)
SotorasibPhase 2Advanced Solid Tumors
Est. primary completion 2028-07-01 · NCT07172919 · CT.gov ↗
What to watch
August 2028 (1)
Inebilizumab + BlinatumomabPhase 2Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
Est. primary completion 2028-08-06 · NCT06570798 · CT.gov ↗
What to watch
September 2028 (2)
maridebart cafraglutide · MariTidePhase 3Diabetes Mellitus, Type 2
Est. primary completion 2028-09-06 · NCT07866066 · CT.gov ↗
What to watch
SotorasibPhase 3Metastatic Colorectal Cancer
Est. primary completion 2028-09-25 · NCT06252649 · CT.gov ↗
What to watch
2029 (6)
January 2029 (2)
TarlatamabPhase 3Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
Est. primary completion 2029-01-04 · NCT07005128 · CT.gov ↗
What to watch
Etelcalcetide · ParsabivPhase 3Secondary Hyperparathyroidism, Chronic Kidney Disease
Est. primary completion 2029-01-31 · NCT03633708 · CT.gov ↗
What to watch
March 2029 (2)
tezepelumab · TezspirePhase 3Chronic Obstructive Pulmonary Disease (COPD)
Est. primary completion 2029-03-13 · NCT06878261 · CT.gov ↗
What to watch
tezepelumab · TezspirePhase 3Chronic Obstructive Pulmonary Disease (COPD)
Est. primary completion 2029-03-13 · NCT06883305 · CT.gov ↗
What to watch
August 2029 (1)
TarlatamabPhase 2Small Cell Lung Cancer (SCLC)
Est. primary completion 2029-08-10 · NCT06745323 · CT.gov ↗
What to watch
September 2029 (1)
BlinatumomabPhase 3Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Est. primary completion 2029-09-07 · NCT04994717 · CT.gov ↗
What to watch
2030 (4)
February 2030 (1)
apremilast · OtezlaPhase 3Behçet Disease
Est. primary completion 2030-02-07 · NCT04528082 · CT.gov ↗
What to watch
March 2030 (1)
InebilizumabPhase 2Generalized Myasthenia Gravis
Est. primary completion 2030-03-13 · NCT06987539 · CT.gov ↗
What to watch
April 2030 (2)
TarlatamabPhase 3Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Est. primary completion 2030-04-02 · NCT06211036 · CT.gov ↗
What to watch
TarlatamabPhase 3Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Est. primary completion 2030-04-20 · NCT06117774 · CT.gov ↗
What to watch
2031 (6)
March 2031 (1)
BlinatumomabPhase 1/2Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Est. primary completion 2031-03-06 · NCT07134088 · CT.gov ↗
What to watch
June 2031 (1)
InebilizumabPhase 2Immunoglobulin G4-related Disease
Est. primary completion 2031-06-10 · NCT07222553 · CT.gov ↗
What to watch
July 2031 (1)
InebilizumabPhase 3Autoimmune Hepatitis, AIH
Est. primary completion 2031-07-30 · NCT07598825 · CT.gov ↗
What to watch
September 2031 (1)
InebilizumabPhase 3Glomerulonephritis, Membranous
Est. primary completion 2031-09-27 · NCT07851220 · CT.gov ↗
What to watch
October 2031 (1)
OlpasiranPhase 3Cardiovascular Disease
Est. primary completion 2031-10-20 · NCT07136012 · CT.gov ↗
What to watch
December 2031 (1)
BlinatumomabPhase 3Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
Est. primary completion 2031-12-30 · NCT07223190 · CT.gov ↗
What to watch
2036 (1)
March 2036 (1)
apremilast · OtezlaPhase 3Behçet's Disease, Juvenile Psoriatic Arthritis
Est. primary completion 2036-03-17 · NCT05767047 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(17)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 September 2026Topline resultDazodalibepOASIZ 301 Phase 3 primary endpoint met
Amgen · Source ↗
8 September 2026Topline resultTarlatamabDeLLphi-305 meets its overall-survival primary endpoint at interim analysis
Amgen · Source ↗
27 August 2026Topline resulttezepelumabPhase 3 CROSSING of tezepelumab in eosinophilic esophagitis met both co-primary endpoints
AstraZeneca · Source ↗
5 August 2026WithdrawalLodotraFDA withdraws approval of NDA 202020 (Federal Register 2026-13616)
US, FDA · Source ↗
4 August 2026WithdrawalAvacopanEuropean Commission revokes the EU marketing authorisation of Tavneos (Article 20 review of ADVOCATE data handling)
EU, EMA/EC · European Commission · Source ↗
30 April 2026Withdrawal proposedAvacopanFDA proposes to withdraw approval of TAVNEOS (NDA held by ChemoCentryx, an Amgen company); opportunity for a hearing
US, FDA · FDA (CDER) · Source ↗
12 February 2026ApprovalInebilizumabEuropean Commission approves UPLIZNA for generalized myasthenia gravis
EU, EC · Source ↗
11 December 2025ApprovalInebilizumabFDA approves UPLIZNA for generalized myasthenia gravis
US, FDA · Amgen · Source ↗
19 November 2025ApprovalTarlatamabFDA grants full approval to Imdelltra in ES-SCLC
US, FDA · Source ↗
17 October 2025ApprovaltezepelumabFDA approves Tezspire for CRSwNP
US, FDA · Source ↗
October 2025Topline resultEvolocumabVESALIUS-CV Phase 3 met dual primary endpoints
3 April 2025ApprovalInebilizumabFDA approves UPLIZNA for IgG4-RD
US, FDA · Source ↗

The 12 most recent of 17 past events are shown.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$10.4B$2.1B$13.2B—$4.2B operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$10.1B$1.9B$14.0B—$4.0B operating cash flowreport ↗
2026-Q1$8.6B$1.7B$12.0B—$2.2B operating cash flowreport ↗
2025-Q3$9.6B$1.9B$9.4B—$4.7B operating cash flowreport ↗
2025-Q2$9.2B$1.7B$8.0B—$2.3B operating cash flowreport ↗
2025-Q1$8.1B$1.5B$8.8B—$1.4B operating cash flowreport ↗
2024-Q3$8.5B$1.4B$9.0B—$3.6B operating cash flowreport ↗
2024-Q2$8.4B$1.4B$9.3B—$2.5B operating cash flowreport ↗
2024-Q1$7.4B$1.3B$9.7B$113M$689M operating cash flowreport ↗
2023-Q3$6.9B$1.1B$34.7B+ $0 short-term inv.—$2.8B operating cash flowreport ↗
2023-Q2$7.0B$1.1B$34.2B+ $0 short-term inv.—$4.1B operating cash flowreport ↗
2023-Q1$6.1B$1.1B$31.6B+ $1.0M short-term inv.—$1.1B operating cash flowreport ↗
2022-Q3$6.7B$1.1B$9.5B+ $2.0B short-term inv.—$3.0B operating cash flowreport ↗
2022-Q2$6.6B$1.0B$5.2B+ $2.0B short-term inv.—$1.9B operating cash flowreport ↗
2022-Q1$6.2B$959M$6.5B+ $16M short-term inv.—$2.2B operating cash flowreport ↗
2021-Q3$6.7B$1.4B$12.0B+ $952M short-term inv.—$2.4B operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$36.8B$7.3B$9.1B—$10.0B operating cash flowreport ↗

Amgen reported full-year 2025 total revenues of $36,751M, up 10.0% YoY, with research and development spend of $7,272M, up 21.9% YoY. Cash and equivalents stood at $9,129M, and the company reported net income of $7,711M for the year.

For 2026, Amgen guided total revenues of $37.0B to $38.4B, GAAP EPS of $15.45 to $16.94, non-GAAP EPS of $21.60 to $23.00, capital expenditures of approximately $2.6B, and share repurchases not exceeding $3B. Pipeline updates included ongoing Phase 3 MariTide studies for obesity and type 2 diabetes, full FDA approval of IMDELLTRA in extensive-stage small cell lung cancer, new UPLIZNA approvals in IgG4-related disease and generalized myasthenia gravis, and a disclosed FDA request to voluntarily withdraw TAVNEOS from the U.S. market, which Amgen stated it did not intend to follow.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$33.4B$6.0B$12.0B—$11.5B operating cash flowreport ↗
2023-FY$28.2B$4.8B$10.9B+ $0 short-term inv.—$8.5B operating cash flowreport ↗
2022-FY$26.3B$4.4B$7.6B+ $1.7B short-term inv.—$9.7B operating cash flowreport ↗
2021-FY$26.0B$4.8B$8.0B+ $48M short-term inv.—$9.3B operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 10 sales ($25.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-06Drake Michael V · directorAward / grant114.026——Form 4
2026-11-06Gibbs David W · directorAward / grant278——Form 4
2026-11-06HOLLEY CHARLES M · directorAward / grant184.614——Form 4
2026-11-06ISHRAK OMAR · directorAward / grant152.035——Form 4
2026-08-13Khosla Rachna · SVP, Business DevelopmentOption exercise1,252$162.60$204KForm 4
2026-08-13Khosla Rachna · SVP, Business DevelopmentOpen-market sale1,252$416.43$521KForm 4
2026-08-13Khosla Rachna · SVP, Business DevelopmentOption exercise (derivative)1,252——Form 4
2026-08-11Khosla Rachna · SVP, Business DevelopmentOpen-market sale2,000$412.57$825KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 3,103 reporting institutions held 428.0M shares ($146.9B, 79.1% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.47,100,472$16.6B
2VANGUARD CAPITAL MANAGEMENT LLC35,014,232$12.3B
3STATE STREET CORP30,548,488$10.7B
4Capital World Investors29,288,343$10.3B
5MORGAN STANLEY15,836,058$5.6B
6GEODE CAPITAL MANAGEMENT, LLC15,430,524$5.4B
7VANGUARD PORTFOLIO MANAGEMENT LLC14,621,148$5.1B
8CHARLES SCHWAB INVESTMENT MANAGEMENT INC12,773,386$4.5B
9PRIMECAP MANAGEMENT CO/CA/8,874,129$3.1B
10JPMORGAN CHASE & CO7,277,837$2.5B
11Capital International Investors7,122,275$2.5B
12WELLS FARGO & COMPANY/MN7,088,010$2.5B
13Capital Research Global Investors6,955,345$2.4B
14NORTHERN TRUST CORP6,217,838$2.2B
15BANK OF AMERICA CORP /DE/5,121,028$1.8B